Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 11,334 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Completed No phase listed Observational

Effectiveness of Ofatumumab in Real-world Practice

NCT06760624
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 20, 2026, 11:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology of Surfactant Protein-B Deficiency

NCT00014859
View directory record Official record
Conditions
Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 1 Year
Enrollment
5,176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine

NCT04206059
View directory record Official record
Conditions
Sleep, Sedation Complication
Interventions
MRI, Quantitative Sensory Testing (QST), Home sleep study, Acoustic stimulation (65 decibels or db) up-slope of EEG with QST, Acoustic stimulation (65db) down-slope of EEG with QST, 0 db with QST, Dexmedetomidine, Breathe-Squeeze Task
Radiation · Diagnostic Test · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

NCT05229562
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
View directory record Official record
Conditions
Cocaine Dependency
Interventions
CPP-115, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 20, 2026, 11:16 AM EDT
Recruiting Phase 2 Interventional

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296
View directory record Official record
Conditions
Proteinuric Kidney Diseases
Interventions
BI 764198, Placebo matching BI 764198
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Huntsville, Alabama • Glendale, California • Granada Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

NCT00571662
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease, Peripheral T-cell Lymphoma
Interventions
Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA), Mycophenolate Mofetil (MMF), G-CSF
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

NCT02077933
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
Interventions
alpelisib, everolimus, exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Fayetteville, Arkansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional Results available

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

NCT03364348
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine
Drug
Lead sponsor
George W. Sledge Jr.
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 20, 2026, 11:16 AM EDT
Not listed Phase 1 Interventional

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

NCT06433791
View directory record Official record
Conditions
Safety
Interventions
Ascorbate-Meglumine
Drug
Lead sponsor
LadeRx LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

NCT01532518
View directory record Official record
Conditions
Colic
Interventions
Nepadutant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
Up to 6 Months
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STI/HIV Intervention Behavioral Intervention Program

NCT04547413
View directory record Official record
Conditions
Sexually Transmitted Infections
Interventions
STI/HIV Intervention Behavioral Intervention Program
Behavioral
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 30 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Fayetteville, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 20, 2026, 11:16 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

NCT06253520
View directory record Official record
Conditions
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

NCT01657682
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Interventions
Crenolanib besylate
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer

NCT04697524
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Support Group Therapy, Symptom Management Service (SMS) Consultation, Quality of Life (QOL) Questionnaires, Interview
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 20, 2026, 11:16 AM EDT
Terminated Phase 1 Interventional

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624
View directory record Official record
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00568880
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, hydroxychloroquine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 20, 2026, 11:16 AM EDT
Terminated Phase 1 Interventional

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

NCT03336580
View directory record Official record
Conditions
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Interventions
PRX004
Drug
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 20, 2026, 11:16 AM EDT
Completed No phase listed Observational

A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

NCT00380796
View directory record Official record
Conditions
COPD, Pulmonary Disease, Chronic Obstructive
Interventions
Collection of safety data for Cohort 1
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
Not listed
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
26
States / cities
Anaheim, California • San Diego, California • Bay Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 20, 2026, 11:16 AM EDT
Terminated No phase listed Observational

A Study to Investigate Cystic Fibrosis Pulmonary Exacerbations and the Lung Microbiome

NCT05088447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Up to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 20, 2026, 11:16 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

NCT00672152
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), B Cell Malignancies
Interventions
WT1 derived peptides
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 20, 2026, 11:16 AM EDT
Active, not recruiting Not applicable Interventional

Assessment of a Non-invasive Device in the Management of Open Abdomen (AbCLO)

NCT06242925
View directory record Official record
Conditions
Open Abdomen
Interventions
AbCLO (Abdominal Wall Closure) Device
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NCT01466374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, BMS-936557 (Anti-IP-10 Antibody)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors

NCT05279690
View directory record Official record
Conditions
Urothelial Cancer, Metastatic Solid Tumor
Interventions
Colchicine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 20, 2026, 11:16 AM EDT